FADS7_Degs1 Inhibitors
Chemical inhibitors of FADS7_Degs1 can act through various mechanisms to impede the protein's function in ceramide metabolism. GW4869, a non-competitive inhibitor of neutral sphingomyelinase, can lead to decreased ceramide levels by restricting the production of ceramide from sphingomyelin, thus indirectly inhibiting FADS7_Degs1 by reducing its substrate availability. Similarly, Fumonisin B1 targets ceramide synthase, curbing the formation of ceramide from sphinganine, and Cerulenin and C75 obstruct fatty acid synthase, limiting the synthesis of long-chain fatty acids, a necessary substrate for the protein's activity, thereby inhibiting FADS7_Degs1. PDMP, an inhibitor of glucosylceramide synthase, can result in reduced ceramide utilization, which might lead to an accumulation of substrates that FADS7_Degs1 would typically process, hindering its function. Furthermore, Myriocin, which inhibits serine palmitoyltransferase, can decrease sphingolipid biosynthesis and consequently reduce substrate availability for FADS7_Degs1.
Continuing with this theme, L-Cycloserine can inhibit serine racemase, potentially limiting the availability of D-serine for sphingolipid synthesis, impacting pathways in which FADS7_Degs1 is involved. Moreover, Tipifarnib and Manumycin A, by inhibiting farnesyltransferase and Ras farnesyltransferase respectively, can disrupt post-translational modifications of proteins that interact with or are necessary for the proper function of FADS7_Degs1. Betulinic Acid, by inducing ceramide accumulation, can affect the equilibrium of lipid synthesis and degradation pathways, leading to the functional inhibition of FADS7_Degs1 due to altered substrate dynamics. Lastly, D-MAPP targets sphingosine kinase, reducing sphingosine-1-phosphate levels, which could impact the sphingolipid rheostat balance, and indirectly lead to inhibition of FADS7_Degs1 by altering the homeostasis of ceramide and other sphingolipids that are central to the protein's activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is a non-competitive inhibitor of neutral sphingomyelinase (nSMase), an enzyme that produces ceramide from sphingomyelin. FADS7_Degs1 is involved in the biosynthesis of ceramide. By inhibiting nSMase, GW4869 can lead to decreased ceramide levels, which in turn can reduce the substrate availability for FADS7_Degs1, resulting in its functional inhibition. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
Fumonisin B1 is a mycotoxin that inhibits ceramide synthase, which catalyzes the formation of ceramide from sphinganine. Since FADS7_Degs1 is involved in ceramide metabolism, the inhibition of ceramide synthesis by Fumonisin B1 can result in reduced substrate availability for FADS7_Degs1, thereby inhibiting its function. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
C75 is a synthetic fatty acid synthase inhibitor. It interferes with the synthesis of long-chain fatty acids. By inhibiting fatty acid synthase, C75 can reduce the availability of fatty acids that are necessary substrates for FADS7_Degs1 activity, thereby inhibiting its function indirectly. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
Cerulenin is an epoxide natural product that inhibits fatty acid synthase. The inhibition of fatty acid synthase leads to a decrease in the levels of long-chain fatty acids, which are substrates for FADS7_Degs1. The resulting decrease in substrate availability can inhibit the function of FADS7_Degs1. | ||||||
Myriocin (ISP-1) | 35891-70-4 | sc-201397 | 10 mg | $150.00 | 8 | |
Myriocin is an inhibitor of serine palmitoyltransferase, the first and rate-limiting enzyme in sphingolipid synthesis. Inhibition of serine palmitoyltransferase results in reduced sphingolipid biosynthesis, which can reduce substrate availability for FADS7_Degs1 and inhibit its function. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib inhibits farnesyltransferase, an enzyme involved in the post-translational modification of proteins by farnesylation. As FADS7_Degs1 may require farnesylated proteins for its activity or localization, inhibition of farnesyltransferase by Tipifarnib could disrupt these processes and inhibit FADS7_Degs1 function. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a selective and potent inhibitor of Ras farnesyltransferase. By inhibiting this enzyme, it can affect the post-translational modification of proteins that interact with FADS7_Degs1, potentially disrupting its function. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid is known to induce ceramide accumulation through the inhibition of acid ceramidase. Increased levels of ceramide can affect the equilibrium of lipid synthesis and degradation pathways, potentially leading to functional inhibition of FADS7_Degs1 due to altered substrate dynamics. | ||||||